Person:
Fanlo Mateo, Patricia

Profile Picture

Email Address

person.page.identifierURI

https://academica-e.unavarra.es/handle/2454/48999

Birth Date

Job Title

Last Name

Fanlo Mateo

First Name

Patricia

person.page.departamento

Ciencias de la Salud

person.page.instituteName

ORCID

person.page.observainves

1173533

person.page.upna

812872

Name

Filters

2017 - 201912020 - 20231
Reset filters

Settings

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Efficacy and safety of anakinra plus standard of care for patients with severe Covid-19: a randomized phase 2/3 clinical trial
    (American Medical Association, 2023) Fanlo Mateo, Patricia; Gracia-Tello, Borja del Carmelo; Fonseca Aizpuru, Eva; Álvarez-Troncoso, Jorge; González, Andrés; Prieto-González, Sergio; Freire, Mayka; Argibay, Ana Belén; Pallarés, Lucio; Todolí, José Antonio; Pérez, Mercedes; Buján-Rivas, Segundo; Ibáñez Beroiz, Berta; Ciencias de la Salud; Osasun Zientziak
    Importance: COVID-19 pneumonia is often associated with hyperinflammation. The efficacy and safety of anakinra in treating patients with severe COVID-19 pneumonia and hyperinflammation are still unclear. Objetive: To assess the efficacy and safety of anakinra vs standard of care alone for patients with severe COVID-19 pneumonia and hyperinflammation. Design, Setting, and Participants: The Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to COVID-19 (ANA-COVID-GEAS) was a multicenter, randomized, open-label, 2-group, phase 2/3 clinical trial conducted at 12 hospitals in Spain between May 8, 2020, and March 1, 2021, with a follow-up of 1 month. Participants were adult patients with severe COVID-19 pneumonia and hyperinflammation. Hyperinflammation was defined as interleukin-6 greater than 40 pg/mL, ferritin greater than 500 ng/mL, C-reactive protein greater than 3 mg/dL (rationale, 5 upper normal limit), and/or lactate dehydrogenase greater than 300 U/L. Severe pneumonia was considered if at least 1 of the following conditions was met: ambient air oxygen saturation 94% or less measured with a pulse oximeter, ratio of partial pressure O2 to fraction of inspired O2 of 300 or less, and/or a ratio of O2 saturation measured with pulse oximeter to fraction of inspired O2 of 350 or less. Data analysis was performed from April to October 2021. Interventions: Usual standard of care plus anakinra (anakinra group) or usual standard of care alone (SoC group). Anakinra was given at a dose of 100 mg 4 times a day intravenously. Main Outcomes and Maesures: The primary outcome was the proportion of patients not requiring mechanical ventilation up to 15 days after treatment initiation, assessed on an intention-totreat basis. Results: A total of 179 patients (123 men [69.9%]; mean [SD] age, 60.5 [11.5] years) were randomly assigned to the anakinra group (92 patients) or to the SoC group (87 patients). The proportion of patients not requiring mechanical ventilation up to day 15 was not significantly different between groups (64 of 83 patients [77.1%] in the anakinra group vs 67 of 78 patients [85.9%] in the SoC group; risk ratio [RR], 0.90; 95% CI, 0.77-1.04; P = .16). Anakinra did not result in any difference in time to mechanical ventilation (hazard ratio, 1.72; 95% CI, 0.82-3.62; P = .14). There was no significant difference between groups in the proportion of patients not requiring invasive mechanical ventilation up to day 15 (RR, 0.99; 95% CI, 0.88-1.11; P > .99). Conclusions and relevance: In this randomized clinical trial, anakinra did not prevent the need for mechanical ventilation or reduce mortality risk compared with standard of care alone among hospitalized patients with severe COVID-19 pneumonia. Trial Registration: ClinicalTrials.gov Identifier: NCT04443881
  • Thumbnail Image
    PublicationOpen Access
    Estudio multidisciplinar de las causas sistémicas de uveítis en 500 pacientes adultos en Navarra
    (2017) Fanlo Mateo, Patricia; Tiberio López, Gregorio; Heras Mulero, Henar; Espinosa Garriga, Gerard; Ciencias de la Salud; Osasun Zientziak
    El objetivo de esta tesis doctoral es escribir las características de los pacientes con uveítis valorados en una unidad multidisciplinar de referencia del norte de España. Material y métodos: Análisis retrospectivo de los pacientes con uveítis valorados en la unidad multidisciplinar del Complejo Hospitalario de Navarra desde enero de 2010 hasta marzo del 2015. Se analizó las características demográficas, procedencia, tipos de uveítis, lateralidad, etiología y se compararon estas características con las de dos series de pacientes de Castilla y León y Barcelona. Resultados: Se analizaron un total de 500 pacientes, 50% mujeres y con una edad media de 47,9 ± 16,4 años. El 61% de las uveítis fueron anteriores, 23% posteriores, 14% panuveítis y el 2% de localización intermedia. El 31,2% fueron no clasificables, seguidas de la enfermedad sistémica no infecciosa en el 29,2%. La espondilitis anquilopoyética (10,8%), la infección por virus herpes (9,2%) y la toxoplasmosis (7,8%) fueron las tres causas más frecuentes. En comparación con las otras dos series, en la de este estudio se encontró una mayor proporción de uveítis anteriores unilaterales. Además, en Navarra los pacientes presentaron mayor prevalencia de uveítis anterior unilateral y de uveítis idiopáticas en relación con la serie de Barcelona. Conclusiones: Los datos de nuestro estudio demuestran características similares con las uveítis de otras regiones de nuestro país. Las uveítis anteriores unilaterales y las idiopáticas fueron las más frecuentes en nuestra serie.